MedTrace Logo

Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening

NCT02156869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1170

Last updated 2014-06-05

No results posted yet for this study

Summary

Although the number of recommendations against systematic screening of prostate cancer, 70% of patients still request testing because they overestimate the benefits and are unaware of the limitations.

The investigators aim is to assess the impact of a short printed decision aid presenting benefits and limits of screening, on patients' intent to undergo prostate cancer screening.

Conditions

Interventions

OTHER

Decision aid

Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.

Sponsors & Collaborators

  • University of Paris 5 - Rene Descartes

    collaborator OTHER

  • University Paris 7 - Denis Diderot

    lead OTHER

Principal Investigators

  • Viet Thi Tran, MD · Paris Diderot University

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-02-28
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02156869 on ClinicalTrials.gov